Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine

Antiviral Research

Volumn 55, Issue 1, 2002, Pages 141-150

  Tatti, Kathleen M ^a   Korba, Brent E ^b   Stang, Heather L ^a   Peek, Simon ^c   Gerin, John L ^b   Tennant, Bud C ^c   Schinazi, Raymond F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

Lamivudine (3TC); Viral drug resistance; Woodchuck (Marmota monax); Woodchuck hepatitis virus (WHV)

Indexed keywords

ALANINE; AMINO ACID; DNA POLYMERASE; LAMIVUDINE; POLYPEPTIDE; THREONINE; VIRUS ANTIGEN; VIRUS PROTEIN; ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; CELL CULTURE; CODON; CONTROLLED STUDY; DNA REPLICATION; DNA SEQUENCE; DRUG SENSITIVITY; GENETIC TRANSFECTION; HEPATITIS; HEPATITIS VIRUS; HUMAN; MOLECULAR CLONING; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; STRUCTURAL GENE; VIRUS CARRIER; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE; WOODCHUCK; AMINO ACID SEQUENCE; ANIMAL; BLOOD; COMPARATIVE STUDY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HEPATITIS B VIRUS; MOLECULAR GENETICS; SCIURIDAE; SEQUENCE ALIGNMENT; VIROLOGY;

AMINO ACID SEQUENCE; ANIMAL; ANTIVIRAL AGENTS; CLONING, MOLECULAR; COMPARATIVE STUDY; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, MICROBIAL; HEPATITIS B VIRUS, WOODCHUCK; LAMIVUDINE; MARMOTA; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE ALIGNMENT; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TRANSFECTION; VIRUS REPLICATION; ANIMALS;

ANIMALIA; HEPATITIS B VIRUS; MARMOTA; MARMOTA MONAX; WOODCHUCK HEPATITIS B VIRUS;

EID: 0035997941     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00019-0     Document Type: Article

References (38)

1. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
2. Hepatitis B virus mutations during antiviral therapy in a patient following liver transplantation
3. Clinical experience with famciclovir against hepatitis B virus
4. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
5. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease
6. Hepatocellular carcinoma and hepatitis B virus
7. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication
8. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
9. Sequence comparison of woodchuck hepatitis virus replicative forms shows conservation of the genome
10. Lamivudine as initial treatment for chronic hepatitis B in the United States
11. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues
12. Generation of duck hepatitis virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2′ and 3′-dideoxy-3′-thiacytidine] in vitro
13. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L (-) SddC (3TC) resistance
14. The mechanism of action and cellular pharmacology of anti-hepatitis B virus agents
15. Nucleotide sequence of a cloned woodchuck hepatitis virus genome; Comparision with the hepatitis B virus sequence
16. The molecular biology of the hepatitis B viruses
17. Complete nucleotide sequence of a molecular clone of woodchuck hepatitis virus that is infectious in the natural host
18. Pharmacodynamics of (-)-β-2′,3′-dideoxy-3′-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans
19. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells
20. Treatment of chronic woodchuck hepatitis virus infection in the eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans
21. Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection
22. Lamivudine therapy of WHV infected woodchucks
23. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
24. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
25. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
26. Pharmacokinetics of (-) 2′, 3′-dideoxy-3′-thiacytidine in woodchucks
27. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
28. Pure nucleoside enantiomers of (-)-2′, 3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro
29. Comparative activation of 2′-deoxycytidine and antiviral oxathiolane cytosine nucleosides by different mammalian liver extracts
30. Cell-based and animal models for hepatitis B and C viruses
31. Molecular analysis of the function of direct repeats and a polypurine tract for plus strand DNA priming in woodchuck hepatitis virus
32. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo
33. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thiacytidine
34. A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2′,3′-dideoxy-3′-thiacytidine
35. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
36. Influence of age on the response to experimental woodchuck hepatitis virus infection
37. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
38. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine